S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Enzo Biochem, Inc. (ENZ)
Chart Events
Performance Outlook
| Previous Close | 2.4000 |
| Open | 2.3915 |
| Bid | 2.0300 x 1100 |
| Ask | 2.9000 x 800 |
| Day's Range | 2.3100 - 2.4300 |
| 52 Week Range | 2.2300 - 4.1500 |
| Volume | |
| Avg. Volume | 59,831 |
| Market Cap | 115.363M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | 23.80 |
| EPS (TTM) | 0.1000 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Investors in Enzo Biochem (NYSE:ENZ) have unfortunately lost 73% over the last five years
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held...
- GlobeNewswire
Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test
Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19 PCR and CT/NG/TVNEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE® HPV test. The AMPIPROBE® HPV test is Enzo’s PCR-based test designed to detect 14 high-risk human papillomavirus (HPV) vari
- GlobeNewswire
Enzo Biochem Reports Results of its Annual Meeting of Shareholders
FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced the approval of all proposals presented at its most recent Annual Meeting of Shareholders. “Approval of these proposals improves our corporate governance and allows our refreshed leadership team to further prioritize shareholder-friendly initiatives,” stated Hamid Erfanian, Chief Execu
